Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD

2.420

-0.150 (-5.84%)

At close: Jul 2, 2024, 4:00 PM

2.479

+0.059 (2.44%)

After-hours: Jul 2, 2024, 6:27 PM EDT

Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Revenue	234.04	132.57	77.8	15.33	0.41	Upgrade
Revenue Growth (YoY)	76.55%	70.40%	407.65%	3610.65%	-88.92%	Upgrade
Cost of Revenue	74.36	51.67	23.41	4.77	0	Upgrade
Gross Profit	159.68	80.9	54.39	10.56	0.41	Upgrade
Selling, General & Admin	297.73	223.93	198.82	151.85	62.01	Upgrade
Research & Development	79.41	101.29	116.26	125.8	102.86	Upgrade
Other Operating Expenses	99.31	97.64	13.99	6.08	0	Upgrade
Operating Expenses	476.45	422.86	329.06	283.72	164.87	Upgrade
Operating Income	-316.78	-341.96	-274.68	-273.16	-164.46	Upgrade
Interest Expense / Income	19.36	16.47	6.27	15.15	0	Upgrade
Other Expense / Income	-12.45	-2.71	0.36	-3.6	-5.03	Upgrade
Pretax Income	-323.69	-355.72	-281.31	-284.71	-159.43	Upgrade
Income Tax	0.3	0.7	0	-2.62	0	Upgrade
Net Income	-323.99	-356.42	-281.31	-282.09	-159.43	Upgrade
Shares Outstanding (Basic)	85	73	68	58	43	Upgrade
Shares Outstanding (Diluted)	85	73	68	58	43	Upgrade
Shares Change	16.35%	7.71%	16.37%	33.47%	20.15%	Upgrade
EPS (Basic)	-3.83	-4.90	-4.17	-4.86	-3.67	Upgrade
EPS (Diluted)	-3.83	-4.90	-4.17	-4.86	-3.67	Upgrade
Free Cash Flow	-223.46	-196.76	-231.91	-182.6	-109.39	Upgrade
Free Cash Flow Per Share	-2.64	-2.71	-3.44	-3.15	-2.52	Upgrade
Gross Margin	68.23%	61.03%	69.91%	68.88%	100.00%	Upgrade
Operating Margin	-135.35%	-257.95%	-353.06%	-1782.46%	-39820.58%	Upgrade
Profit Margin	-138.43%	-268.87%	-361.59%	-1840.71%	-38602.66%	Upgrade
Free Cash Flow Margin	-95.48%	-148.42%	-298.10%	-1191.52%	-26486.92%	Upgrade
EBITDA	-290.64	-300.1	-255.18	-259.31	-156.52	Upgrade
EBITDA Margin	-124.18%	-226.38%	-328.01%	-1692.08%	-37898.31%	Upgrade
Depreciation & Amortization	13.69	39.15	19.85	10.25	2.91	Upgrade
EBIT	-304.33	-339.25	-275.04	-269.56	-159.43	Upgrade
EBIT Margin	-130.03%	-255.91%	-353.53%	-1758.96%	-38602.66%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).